Room 4331, 3th building, high-tech industrial park, yizhi road, qingshan district, wuhan, China
Home ProductsSex Enhancing Drugs

Effective 25mg Pills Sex Enhancing Drugs Clomifene Citrate Clomid CAS 50-41-9

Effective 25mg Pills Sex Enhancing Drugs Clomifene Citrate Clomid CAS 50-41-9

    • Effective 25mg Pills Sex Enhancing Drugs Clomifene Citrate Clomid CAS 50-41-9
    • Effective 25mg Pills Sex Enhancing Drugs Clomifene Citrate Clomid CAS 50-41-9
    • Effective 25mg Pills Sex Enhancing Drugs Clomifene Citrate Clomid CAS 50-41-9
  • Effective 25mg Pills Sex Enhancing Drugs Clomifene Citrate Clomid CAS 50-41-9

    Product Details:

    Place of Origin: China, Hubei
    Brand Name: bodybiological
    Certification: ISO9001,SGS
    Model Number: 50-41-9

    Payment & Shipping Terms:

    Minimum Order Quantity: 100pills
    Price: USD1/pill
    Packaging Details: 100pills/Bag
    Delivery Time: Within 24 hours after the payment
    Payment Terms: T/T, Western Union, MoneyGram
    Supply Ability: 35000pills/month
    Contact Now
    Detailed Product Description
    Keywords: Clomid Alias: Clomiphene Citrate
    Apperance: White Powder CAS: 50-41-9
    Shipping Way: FEDEX, TNT, DHL, UPS, HK EMS... Payment Terms: Western Union, Money Gram, T/T
    Policy: Resending Policy Shelf Life: Two Years
    Storage: Ventilation Low Temperature Drying Transport Package: 1kg/Aluminium Foil Bag Or As Required

    Antiestrogen Steroid Hormones Powder 50-41-9 Clomifene Citrate Clomid

     

    whatsapp: +8613264710010

     

    Clomid Description

    Clomid (clomiphene citrate tablets USP) is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy] triethylamine citrate (1:1). It has the molecular formula of C26H28ClNO • C6H8O7 and a molecular weight of 598.09. It is represented structurally as:
    Effective 25mg Pills Sex Enhancing Drugs Clomifene Citrate Clomid CAS 50-41-9

    Clomiphene citrate is a white to pale yellow, essentially odorless, crystalline powder. It is freely soluble in methanol; soluble in ethanol; slightly soluble in acetone, water, and chloroform; and insoluble in ether.

    Clomid is a mixture of two geometric isomers [cis (zuclomiphene) and trans (enclomiphene)] containing between 30% and 50% of the cis-isomer.

    Each white scored tablet contains 50 mg clomiphene citrate USP. The tablet also contains the following inactive ingredients: corn starch, lactose, magnesium stearate, pregelatinized cornstarch, and sucrose.

    Clomid - Clinical Pharmacology

    Action

    Clomid is a drug of considerable pharmacologic potency. With careful selection and proper management of the patient, Clomid has been demonstrated to be a useful therapy for the anovulatory patient desiring pregnancy.

    Clomiphene citrate is capable of interacting with estrogen-receptor-containing tissues, including the hypothalamus, pituitary, ovary, endometrium, vagina, and cervix. It may compete with estrogen for estrogen-receptor-binding sites and may delay replenishment of intracellular estrogen receptors. Clomiphene citrate initiates a series of endocrine events culminating in a preovulatory gonadotropin surge and subsequent follicular rupture. The first endocrine event in response to a course of clomiphene therapy is an increase in the release of pituitary gonadotropins. This initiates steroidogenesis and folliculogenesis, resulting in growth of the ovarian follicle and an increase in the circulating level of estradiol. Following ovulation, plasma progesterone and estradiol rise and fall as they would in a normal ovulatory cycle.

    Available data suggest that both the estrogenic and antiestrogenic properties of clomiphene may participate in the initiation of ovulation. The two clomiphene isomers have been found to have mixed estrogenic and antiestrogenic effects, which may vary from one species to another. Some data suggest that zuclomiphene has greater estrogenic activity than enclomiphene.

    Clomiphene citrate has no apparent progestational, androgenic, or antiandrogenic effects and does not appear to interfere with pituitary-adrenal or pituitary-thyroid function.

    Although there is no evidence of a "carryover effect" of Clomid, spontaneous ovulatory menses have been noted in some patients after Clomid therapy.

    Pharmacokinetics

    Based on early studies with 14C-labeled clomiphene citrate, the drug was shown to be readily absorbed orally in humans and excreted principally in the feces. Cumulative urinary and fecal excretion of the 14C averaged about 50% of the oral dose and 37% of an intravenous dose after 5 days. Mean urinary excretion was approximately 8% with fecal excretion of about 42%.

    Some 14C label was still present in the feces 6 weeks after administration. Subsequent single-dose studies in normal volunteers showed that zuclomiphene (cis) has a longer half-life than enclomiphene (trans). Detectable levels of zuclomiphene persisted for longer than a month in these subjects. This may be suggestive of stereo-specific enterohepatic recycling or sequestering of the zuclomiphene. Thus, it is possible that some active drug may remain in the body during early pregnancy in women who conceive in the menstrual cycle during Clomid therapy.

     

    Clomiphene citrate Specifications:

     

    Test Items Specification Test Results
    Appearance White or off-white powder white powder
    Identification UV conform Conforms
    Organic nitrogenous Conforms Conforms
    Citrate Conforms Conforms
    Water Not more than 1.0% 0.35%
    Heavy water Not more than 0.002% Conforms
    Related impuries Related compound A:Not more than 2.0% 0.84%
    Individual:Not more than 0.5% 0.36%
    (Z)isomer Conforms Conforms
    Organicvolatile impuritise Conforms  
    Assay Between98.0~102.0% 99.5%

     

    Clinical Studies

    During clinical investigations, 7578 patients received Clomid, some of whom had impediments to ovulation other than ovulatory dysfunction . In those clinical trials, successful therapy characterized by pregnancy occurred in approximately 30% of these patients.

    There were a total of 2635 pregnancies reported during the clinical trial period. Of those pregnancies, information on outcome was only available for 2369 of the cases. Table 1 summarizes the outcome of these cases.

    Of the reported pregnancies, the incidence of multiple pregnancies was 7.98%: 6.9% twin, 0.5% triplet, 0.3% quadruplet, and 0.1% quintuplet. Of the 165 twin pregnancies for which sufficient information was available, the ratio of monozygotic to dizygotic twins was about 1:5. Table 1 reports the survival rate of the live multiple births.

    A sextuplet birth was reported after completion of original clinical studies; none of the sextuplets survived (each weighed less than 400 g), although each appeared grossly normal.

     

    Table 1. Outcome of Reported Pregnancies in Clinical Trials (n = 2369)    

     

    Includes 28 ectopic pregnancies, 4 hydatiform moles, and 1 fetus papyraceous.

    Indicates percentage of surviving infants from these pregnancies.

    Pregnancy Wastage    
    Spontaneous Abortions 483*  
    Stillbirths 24  
    Live Births    
    Single Births 1697 98.16%
    Multiple Births 165 83.25%

     

     

    Effective 25mg Pills Sex Enhancing Drugs Clomifene Citrate Clomid CAS 50-41-9

    Contact Details
    Wuhan Body Biological Co.,Ltd

    Contact Person: Viki

    Tel: +8613264710010

    Send your inquiry directly to us (0 / 3000)

    Other Products